Yan Ye, Wenzhen Zhong, Ruifeng Luo, Hongzhi Wen, Ziyang Ma, Shanshan Qi, Xiaoqin Han, Wenbiao Nie, Degui Chang, Runchun Xu, Naijing Ye, Fei Gao, Peihai Zhang
BACKGROUND: The complex etiology and pathogenesis underlying Chronic Non-Bacterial Prostatitis (CNP), coupled with the existence of a Blood Prostate Barrier (BPB), contribute to a lack of specificity and poor penetration of most drugs. Emodin (EMO), a potential natural compound for CNP treatment, exhibits commendable anti-inflammatory, anti-oxidant, and anti-fibrosis properties but suffers from the same problems as other drugs. METHODS: By exploiting the recognition properties of lactoferrin (LF) receptors that target intestinal epithelial cells (NCM-460) and prostate epithelial cells (RWPE-1), a pathway is established for the transrectal absorption of EMO to effectively reach the prostate...
January 18, 2024: Journal of Nanobiotechnology